Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sleep Goal Index (SGI) - A new success outcome criteria on 618 OSA patients.

The Medical journal of Malaysia·2025
Same author

Compliance of vendors with legislation restricting the sale of tobacco near educational institutions in India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2022
Same author

SLEEP-GOAL: A multicenter success criteria outcome study on 302 obstructive sleep apnoea (OSA) patients.

The Medical journal of Malaysia·2020
Same author

A prospective, randomized, placebo-controlled trial of on-Demand vs. nightly sildenafil citrate as assessed by Rigiscan and the international index of erectile function.

Andrology·2015
Same author

Mandibular facial talon cusp: a rare case report.

Annals of medical and health sciences research·2014
Same author

Delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: proposal of an evidence-based combined clinical and imaging reference standard.

AJNR. American journal of neuroradiology·2013

Related Experiment Video

Updated: Jun 26, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Drugs designed to improve endothelial function: effects on erectile dysfunction.

A W Shindel1, S Kishore, T F Lue

  • 1Department of Urology, University of California-San Francisco, 400 Parnassus Street, San Francisco, CA 94143, USA.

Current Pharmaceutical Design
|January 9, 2009
PubMed
Summary
This summary is machine-generated.

Vascular medications targeting endothelial dysfunction may improve erectile dysfunction (ED). Drugs like ACE inhibitors and ARBs show promise, while statins and oral hypoglycemics may offer adjunctive benefits for ED management.

Related Experiment Videos

Last Updated: Jun 26, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

Area of Science:

  • Cardiovascular Medicine
  • Urology
  • Pharmacology

Background:

  • Endothelial dysfunction (EtD) is a key factor in vascular disease and erectile dysfunction (ED).
  • Cardiovascular medications often impact endothelial function.
  • Understanding these effects can inform ED treatment strategies.

Purpose of the Study:

  • To review current endothelial-active drugs.
  • To discuss evidence for their use in managing ED.
  • To explore potential therapeutic applications for ED.

Main Methods:

  • Conducted a PubMed query using terms related to endothelial dysfunction, erectile dysfunction, and pharmaceuticals.
  • Reviewed and summarized relevant scientific literature.
  • Focused on drugs with known endothelial effects.

Main Results:

  • Several cardiovascular drug classes, including statins, ACE inhibitors (ACEI), Angiotensin Receptor Blockers (ARB), Endothelin Receptor Antagonists (ERA), beta blockers, and oral hypoglycemics, affect endothelial function.
  • Some of these drugs have demonstrated improvements in penile erection.
  • ACEI and ARB show significant promise for ED management, with statins and oral hypoglycemics as potential adjunctive therapies.

Conclusions:

  • Drugs that enhance endothelial function, particularly in penile vasculature, offer a promising approach to treating ED.
  • ACEI and ARB are strong candidates for ED therapy.
  • Improving endothelial function may help reverse ED, offering an advantage over current on-demand treatments.